Literature DB >> 11790884

Potential cellular signatures of viral infections in human hematopoietic cells.

J Mikovits1, F Ruscetti, W Zhu, R Bagni, D Dorjsuren, R Shoemaker.   

Abstract

Expression profiling of cellular genes was performed using a 10,000 cDNA human gene array in order to identify expression changes following chronic infection of human hematopoietic cells with Kaposi's Sarcoma-associated Virus (KSHV) also known as Human Herpesvirus 8 (HHV8) and Human T cell leukemia virus-1 (HTLV-1). We performed cell-free in vitro infection of primary bone marrow derived CD34+ cells using semi-purified HHV8 and a mature IL-2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1. Thirty days post infection, mRNA was isolated from infected cultures and uninfected controls and submitted for microarray analysis. More than 400 genes were differentially expressed more than two-fold following HHV8 infection of primary bone marrow derived CD34+ cells. Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold. In contrast, less than 100 genes were differentially expressed more than two-fold following chronic infection of a mature T cell line with HTLV-1. Of these, only cdc7 was up-regulated more than 3.5 fold. These data may provide insight into cellular signatures of infection useful for diagnosis of infection as well as potential targets for therapeutic intervention.

Entities:  

Mesh:

Year:  2001        PMID: 11790884      PMCID: PMC3850588          DOI: 10.1155/2001/896953

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  8 in total

1.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

2.  Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin.

Authors:  Hsei-Wei Wang; Tyson V Sharp; Andrew Koumi; Georgy Koentges; Chris Boshoff
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

3.  Conditional screening for ultra-high dimensional covariates with survival outcomes.

Authors:  Hyokyoung G Hong; Jian Kang; Yi Li
Journal:  Lifetime Data Anal       Date:  2016-12-08       Impact factor: 1.588

4.  Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  J Virol       Date:  2021-11-24       Impact factor: 6.549

5.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.

Authors:  Casey J Fox; Peter S Hammerman; Ryan M Cinalli; Stephen R Master; Lewis A Chodosh; Craig B Thompson
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

6.  KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo.

Authors:  William Wu; Jeffrey Vieira; Nancy Fiore; Prabal Banerjee; Michelle Sieburg; Rosemary Rochford; William Harrington; Gerold Feuer
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

7.  Human T-cell leukemia virus type 1 tax oncoprotein suppression of multilineage hematopoiesis of CD34+ cells in vitro.

Authors:  Adam Tripp; Yingxian Liu; Michelle Sieburg; Joanne Montalbano; Stephen Wrzesinski; Gerold Feuer
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.

Authors:  Fang Cheng; Magdalena Weidner-Glunde; Markku Varjosalo; Eeva-Marja Rainio; Anne Lehtonen; Thomas F Schulz; Päivi J Koskinen; Jussi Taipale; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.